The total return over the past 12 months is +31.55% vs. +16.94% for the S&P 500. So far it's up +56.54% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +31.55% | +22.16% | (41.77%) | N/A | N/A | N/A |
| Total Return CAGR | +31.55% | +22.16% | (41.77%) | N/A | N/A | N/A |
| Revenue CAGR | +2.33% | +29.77% | +0.65% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
C4 Therapeutics, Inc. (CCCC)
| Year | Start price | End price | CCCC Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.91 | $2.99 | +56.54% | +14.51% | +42.03% |
| 2025 | $3.60 | $1.91 | (46.94%) | +17.72% | (64.66%) |
| 2024 | $5.65 | $3.60 | (36.28%) | +24.89% | (61.17%) |
| 2023 | $5.90 | $5.65 | (4.24%) | +26.19% | (30.43%) |
| 2022 | $32.20 | $5.90 | (81.68%) | (18.17%) | (63.51%) |
| 2021 | $33.13 | $32.20 | (2.81%) | +28.74% | (31.55%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
